



#### **Global COVID-19 Clinical Platform**

### **NOVEL CORONAVIRUS (COVID-19) - RAPID VERSION**

### **DESIGN OF THIS CASE RECORD FORM (CRF)**

This CRF has 3 modules:

**Module 1** to be completed on the first day of admission to the health centre.

**Module 2** to be completed on first day of admission to ICU or high dependency unit. Module 2 should also be completed daily for as many days as resources allow. Continue to follow-up patients who transfer between wards.

**Module 3** to be completed at discharge or death.

#### **GENERAL GUIDANCE**

- The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected retrospectively if the patient is enrolled after the admission date.
- Participant Identification Numbers consist of a site code and a participant number.
   You can obtain a site code and register on the data management system by contacting <a href="mailto:ncov@isaric.org">ncov@isaric.org</a>.
   Participant numbers should be assigned sequentially for each site beginning with 00001. In the case of a single site recruiting participants on different wards, or where it is otherwise difficult to assign sequential numbers, you can assign numbers in blocks or incorporate alpha characters. E.g. Ward X will assign numbers from 00001 or A0001 onwards and Ward Y will assign numbers from 50001 or B0001 onwards. Enter the Participant Identification Number at the top of every page.
- Data are entered to the central electronic REDCap database at <a href="https://ncov.medsci.ox.ac.uk">https://ncov.medsci.ox.ac.uk</a> or to your site/network's independent database. Printed paper CRFs may be used and the data can be typed into the electronic database afterwards.
- Complete every section. Questions marked "If yes,..." should be left blank when they do not apply (i.e. when the answer is not yes).
- Selections with square boxes (□) are single selection answers (choose one answer only).
- Selections with circular boxes (O) are multiple selection answers (choose all that apply).
- Mark 'Unknown' for any data that are not available or unknown.
- Avoid recording data outside of the dedicated areas.
- If using paper CRFs, we recommend writing clearly in ink, using BLOCK-CAPITAL LETTERS.
- Place an (X) in the boxes to mark the answer. To make corrections, strike through (-----) the data you wish to delete and write the correct data above it. Please initial and date all corrections.
- Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder.
- Please transfer all paper CRF data to the electronic database. All paper CRFs can be stored by the institution responsible for them. All data should be transferred to the secure electronic database.
- Please enter data on the electronic data capture system at <a href="https://ncov.medsci.ox.ac.uk">https://ncov.medsci.ox.ac.uk</a>. If your site would like to collect data independently, we can support the establishment of locally hosted databases.
- Please contact us at <a href="mailto:ncov@isaric.org">ncov@isaric.org</a>. If we can help with databases, if you have comments and to let us know that you are using the forms.





PARTICIPANT ID I	11	11	- 11	- 11		- 11	- 11	- 11	

# MODULE1: complete on admission/enrolment

Site name				Country						
Date of enrolment [_D_][_D_]/[_M		_2_][_0	)_][_Y_][	<u>Y_</u> ]						
CLINICAL INCLUSION CRITERI										
Proven or suspected infection with	n pathoge	en of Pu	ublic Hea	alth Interest □Yes □No						
One or more   A history	of self-re	eported	l feverish	ness or measured fever of ≥ 3	38₀C □Yes	s □No				
of these   Cough					□Yes	s □No				
during this   Dyspnoe	ea (shortr	ness of	breath) (	OR Tachypnoea*	□Yes	s □No				
illness   Clinical	suspicion	of ARI	despite	not meeting criteria above	□Yes	s □No				
* respiratory rate ≥50 breaths/min for	<1 year; ≥	:40 for 1	-4 years;	≥30 for 5-12 years; ≥20 for ≥13 y	rears					
DEMOGRAPHICS										
Sex at Birth □Male □Female	□Not spe	cified	Date of	hirth [ D 1[ D 1/[ M 1[ M 1/	/	1 V 1				
If date of birth is unknown, record	•				ʹ┖┈┼┈╢┈┼┈╢┈┼╴	_][⊥]				
Healthcare Worker? □Yes □N					□Unknown					
Pregnant? □Yes □No □Unkr				_		wooks				
Tregnant: Lifes Live Lonki	IOWII LIN		ıı yes.	Oestational weeks assessin		WCCKS				
DATE OF ONSET AND ADMISS	ON VITA	L SIGN	NS (first	available data at presentatior	n/admission)					
Symptom onset (date of first/ear	iest symp	otom) [_	D_][_D	_]/[_M_][_M_]/[_2_][_0_][_Y_][	_Y_]					
Admission date at this facility [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]										
<b>Temperature</b> [][].[]°C	Heart ra	ate [	_][][_	]beats/min						
Respiratory rate [][]breat	ns/min									
BP [] [] (systolic) [	][][	_](diast	tolic) mm	nHg <b>Severe dehydration</b> D	∃Yes □No □	lUnknow	n			
Sternal capillary refill time >2se	conds [	]Yes [	⊒No □U	Inknown						
Oxygen saturation: [][]%	6 on □ro	om air [		• •	,	circle or	ne)			
Glasgow Coma Score (GCS /15)				utrition □Yes □No □Unknov						
Mid-upper arm circumference [	][]	[]mı	m <b>H</b>	eight: [] [] []cm	Weight: [	][][_	]kg			
CO-MORBIDITIES (existing prior	to admis:	sion) (L	Jnk = Un	known)						
Chronic cardiac disease (not hypertension)	□Yes	□No	□Unk	Diabetes	□Yes	□No	□Unk			
Hypertension	□Yes	□No	□Unk	Current smoking	□Yes	□No	□Unk			
Chronic pulmonary disease	□Yes	□No	□Unk	Tuberculosis	□Yes	□No	□Unk			
Asthma	□Yes	□No	□Unk	Asplenia	□Yes	□No	□Unk			
Chronic kidney disease	□Yes	□No	□Unk	Malignant neoplasm	□Yes	□No	□Unk			
Chronic liver disease	□Yes	□No	□Unk	Other	□Yes	□No	□Unk			
Chronic neurological disorder	□Yes	□No	□Unk	If yes, specify:						
HIV	□Yes-c	n ART	□Yes	s-not on ART □No □Ui	nknown					
PRE-ADMISSION & CHRONIC N	IEDICAT	ION	Were a	any of the following taken w	ithin 14 days o	of admi	ssion?			
Angiotensin converting enzyme in	hibitors (	ACE inl	hibitors)?	? □Yes □No □Unknown						
Angiotensin II receptor blockers (A	ARBs)?			□Yes □No □Unknown						
Non-steroidal anti-inflammatory (N	Non-steroidal anti-inflammatory (NSAID)? □Yes □No □Unknown									





Organization ISARIC			PARTI	CIPANT ID II II I	_	11	
SIGNS AND SYMPTON	MS ON ADMISS	ION (	Unk = Unki	nown)			
History of fever	□Yes	□No	□Unk	Lower chest wall indrawing	□Yes	□No	□Unk
Cough	□Yes	□No		Headache.	□Yes	□No	□Unk
with sputum produc	tion □Yes	□No	□Unk	Altered consciousness/conf	usion □Yes	□No	□Unk
with haemoptysis	□Yes	□No	□Unk	Seizures	□Yes	□No	□Unk
Sore throat	□Yes	□No	□Unk	Abdominal pain	□Yes	□No	□Unk
Runny nose (rhinorrhoea)	. □Yes	□No		Vomiting / Nausea	□Yes	□No	□Unk
Wheezing	□Yes	□No	□Unk	Diarrhoea	□Yes	□No	□Unk
Chest pain.	□Yes	□No	□Unk	Conjunctivitis	□Yes	□No	□Unk
Muscle aches (myalgia)	□Yes	□No	□Unk	Skin rash	□Yes	□No	□Unk
Joint pain (arthralgia).	□Yes	□No	□Unk	Skin ulcers	□Yes	□No	□Unk
Fatigue / Malaise	□Yes	□No	□Unk	Lymphadenopathy	□Yes	□No	□Unk
Shortness of breath .	□Yes	□No	□Unk	Bleeding (Haemorrhage).	□Yes	□No	□Unk
Inability to walk	□Yes	□No	□Unk	If bleeding: specify site(s):			
Other □Yes □No □Un	k If yes, specify:			<b>y</b> , , ,			
			receiving	any of the following?			
MEDICATION							
Extracorporeal (ECMO	<u> </u>			-	? □Yes □No □	Unknow	'n
LABORATORY RESUL	TS ON ADMIS	SION (	*record uni	ts if different from those l	isted)		
Parameter	Value*		Not done	Parameter	Value*		Not done
Haemoglobin (g/L)				Creatinine (µmol/L)			
WBC count (x10 <sub>9</sub> /L)				Sodium (mEq/L)			
Haematocrit (%)				Potassium (mEq/L)			
Platelets (x10 <sub>9</sub> /L)				Procalcitonin (ng/mL)			
APTT/APTR				CRP (mg/L)			
PT (seconds)				LDH (U/L)			
INR				Creatine kinase (U/L)			
ALT/SGPT (U/L)				Troponin (ng/mL)			
Total bilirubin (µmol/L)				ESR (mm/hr)			
AST/SGOT (U/L)				D-dimer (mg/L)			
Urea (BUN) (mmol/L)				Ferritin (ng/mL)			
Lactate (mmol/L)				IL-6 (pg/mL)			





PARTICIPANT ID I	- 11	- 11	- 11	- 11	l I	- 11	- 11	- 11	

# MODULE 2: follow-up (frequency of completion determined by available resources)

Date of follow up [_D_][										
VITAL SIGNS (record r							• .			
Temperature [][]	-	-				- '	-		-	
<b>BP</b> [] [] (sys									□Unkr	ıown
Sternal capillary refill							/15 [][_	-		
Oxygen saturation [					air □ ox	ygen therapy □Unknov	vn	A V P	U (circ	de one)
DAILY CLINICAL FEAT	TUR	· ·	= Unkn					T		
Cough		□Yes	□No	□Ur		Seizures		□Yes	□No	□Unk
and sputum producti Sore throat	on	□Yes □Yes	□No □No	□Ur □Ur		/omiting / Nausea Diarrhoea		□Yes □Yes	□No □No	□Unk □Unk
Chest pain		□Yes	□No	□Ur		Conjunctivitis		□Yes	□No	□Unk
Shortness of breath		□Yes	□No	□Ur		Myalgia		□Yes	□No	□Unk
Confusion		□Yes	□No	□Ur		Other, specify:		□Yes	□No	□Unk
LABORATORY RESUL	.TS (	*record u	ınits if d	lifferer		those listed)				
Parameter	Val	ue*			Not done	Parameter	Value*			Not done
Haemoglobin (g/L)						Creatinine (µmol/L)				
WBC count (x109/L)						Sodium (mEq/L)				
Haematocrit (%)						Potassium (mEq/L)				
Platelets (x10 <sub>9</sub> /L)						Procalcitonin (ng/mL)				
APTT/APTR						CRP (mg/L)				
PT (seconds)						LDH (U/L)				
INR						Creatine kinase (U/L)				
ALT/SGPT (U/L)						Troponin (ng/mL)				
Total bilirubin (µmol/L)						ESR (mm/hr)				
AST/SGOT (U/L)						D-dimer (mg/L)				
Urea (BUN) (mmol/L)						Ferritin (ng/mL)				
Lactate (mmol/L)						IL-6 (pg/mL)				
MEDICATION Is the										
Oral/orogastric fluids?										
Antiviral? □Yes □No			-			•	leuraminid	ase inhibi	tor	
OInterferon alpha OInt					-					
Corticosteroid? □Yes										
			naximur	n daily						
Antibiotic? □Yes □N						tifungal agent? □Yes		nknown		
Antimalarial agent?										
Experimental agent?						•				
Non-steroidal anti-infla		• •	•							
Angiotensin convertin	•	•		•		•	ıknown			
Angiotensin II receptor blockers (ARBs) □Yes □No □Unknown										
SUPPORTIVE CARE Is the patient CURRENTLY receiving any of the following?										
ICU or High Dependency Unit admission? □Yes □No □Unknown										
Oxygen therapy? □Yes □No □Unknown If yes, complete all below:										
O₂ flow volume: □1-5 L/min □6-10 L/min □11-15 L/min □>15 L/min □Unknown										
Source of oxygen: □Piped □Cylinder □Concentrator □Unknown										
Interface: □Nasal prongs □HF nasal cannula □Mask □Mask with reservoir □CPAP/NIV mask □Unknown										
Non-invasive ventilation	•	•		•						
Invasive ventilation (A	- /					Inotropes/vaso	-			
Extracorporeal (ECMO	-	-					position?	P□Yes □	⊒No □	] Unknown
Renal replacement the	rapy	(RRT) o	r dialys	is? [	∃Yes [	□No □Unknown				





PARTICIPANT ID I	1.1	1.1	- 1.1	- 1.1	I I	1.1	- 1.1	1.1	- 1
FAITICIFAITIDI	11	1.1	1.1	11	1 1	1.1	11	1.1	

## **MODULE 3: complete at discharge/death**

DIAGNOSTIC/PATHOGEN TI	ESTING								
	? □Yes □No □Unknown If Y								
Was pathogen testing done	during this illness episode? $\Box$	⊒Yes □No □Unknown <b>If</b>	yes, complete all below:						
Influenza virus: □Positive	e □Negative □Not done <b>If posit</b>	ive, type							
Coronavirus: □Positive □	Negative □Not done <b>If positive</b>	e: □MERS-CoV □SARS-C	CoV-2						
Other respiratory pathoge	en: □Positive □Negative □Not o	done <b>If positive</b> , specify _							
Viral haemorrhagic fever:	: □Positive □Negative □Not don	ne If positive, specify virus	S						
Other pathogen of public	health interest detected: If ye	es, specify:							
	sitive □Negative □Not done <b>Nor</b>								
<b>HIV:</b> □Positive □Negative			<b>3</b>						
COMPLICATIONS: At any time during hospitalisation did the patient experience:									
Shock	□Yes □No □Unknown	Bacteraemia	□Yes □No □Unknown						
Seizure	□Yes □No □Unknown	Bleeding	□Yes □No □Unknown						
Meningitis/Encephalitis	□Yes □No □Unknown	Endocarditis	□Yes □No □Unknown						
Anaemia	□Yes □No □Unknown	Myocarditis/Pericarditis	□Yes □No □Unknown						
Cardiac arrhythmia	□Yes □No □Unknown	Acute renal injury	□Yes □No □Unknown						
Cardiac arrest	□Yes □No □Unknown	Pancreatitis	□Yes □No □Unknown						
Pneumonia	□Yes □No □Unknown	Liver dysfunction	□Yes □No □Unknown						
Bronchiolitis	□Yes □No □Unknown	Cardiomyopathy	□Yes □No □Unknown						
Acute Respiratory Distress Syndrome	□Yes □No □Unknown	Other If Yes, specify	☐Yes ☐No ☐Unknown						
	lised or at discharge, were any		torod?						
	S □No □Unknown Intravenou								
_									
	known If yes: ORibavirin OLo	· <del>-</del>							
	OInterferon beta OOther, specinknown If yes, specify:								
			_						
	Unknown If yes, route: OO		u .						
	aximum daily dose:								
	No □Unknown If yes, specify:								
Antimalarial agent? □Yes [	□No □Unknown <b>If yes,</b> specif	y:							
Experimental agent? □Yes	□No □Unknown <b>If yes,</b> spec	cify:	_						
	t <b>ory (NSAID)</b> □Yes □No □U								
SUPPORTIVE CARE: At ANY	' time during hospitalisation, c	did the patient receive/und	lergo:						
ICU or High Dependency Uni	it admission? □Yes □No □	Unknown If yes, total dur	ration:days						
Date of ICU admission:[_D_]/[_M_]/[_M_]/[_2_][_0_][_Y_][_Y_] □N/A									
	ge:[_D_][_D_]/[_M_][_M_]/[_2_][		t outcome DN/A						
	ye.[_b_][_b_]/[_m_][_m_]/[_b] No □Unknown <b>If yes, comple</b>								
			:days						
O <sub>2</sub> flow volume: O1-5 L/min O6-10 L/min O11-15 L/min O>15 L/min									
Source of oxygen: OPiped OCylinder OConcentrator									
Interface: ONasal prongs OHF nasal cannula OMask OMask with reservoir OCPAP/NIV mask									
Non-invasive ventilation? (e.g. BIPAP, CPAP) □Yes □No □ Unknown If yes, total duration:days									
Invasive ventilation (Any)? □Yes □No □Unknown If yes, total duration:days									
Extracorporeal (ECMO) support?   Yes   No   Unknown If yes, total duration:days									
Prone position? □Yes □No □ Unknown If yes, total duration:days									
Renal replacement therapy (RRT) or dialysis? □Yes □No □Unknown									
Inotropes/vasopressors?   Yes   No   Unknown   If yes, total duration:  days									
OUTCOME									
	☐Hospitalized ☐Transfer to ot	her facility. □Death. □Pallia	ative discharge. □Unknown						
· ·	M_][_M_]/[_2_][_0_][_Y_][_Y_]	•	5 discridings Dominiowii						
			oo bafara illnaas 🗖 Mars -						
וו Discharged alive: Ability t	o self-care at discharge versu		as defore iliness ∟vvorse · □Unknown						